Johnson & Johnson (JNJ) Tax Provisions (2009 - 2026)
Johnson & Johnson's (JNJ) quarterly Tax Provisions came in at $755.0 million in Q1 2026, down 71.31% year-on-year from $2.6 billion in Q1 2025, and up 603.33% quarter-over-quarter from -$150.0 million in Q4 2025.
Johnson & Johnson (JNJ) Tax Provisions (2009 - 2026) Analysis & Trends
Johnson & Johnson has disclosed Tax Provisions across 18 years of filings, most recently posting $755.0 million for Q1 2026.
- Tax Provisions for Q1 2026 came in at $755.0 million, down 71.31% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.9 billion (down 18.65% YoY), and the FY2025 annual result was $5.8 billion, up 120.41% from the prior year.
- Tax Provisions came in at $755.0 million for Q1 2026 at Johnson & Johnson, up from -$150.0 million in the prior quarter.
- In the past five years, Tax Provisions ranged from a high of $2.6 billion in Q1 2025 to a low of -$796.0 million in Q2 2023.
- The 5-year median for Tax Provisions is $862.0 million (2022), against an average of $863.6 million.
- Across the five-year window, Tax Provisions tumbled 211.64% in 2023 and surged 473.42% in 2025, its largest moves.
- Johnson & Johnson's Tax Provisions stood at $862.0 million in 2022, then slipped by 19.49% to $694.0 million in 2023, then slumped by 34.29% to $456.0 million in 2024, then sank by 132.89% to -$150.0 million in 2025, then soared by 603.33% to $755.0 million in 2026.
- The last three Tax Provisions figures came in at $755.0 million (Q1 2026), -$150.0 million (Q4 2025), and $2.3 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | -411.19 Mn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 1.45 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 755.00 Mn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 342.00 Mn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | 709.00 Mn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 265.00 Mn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 559.00 Mn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 461.00 Mn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 561.00 Mn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 755.00 Mn |
| Dec 28, 2025 | -150.00 Mn |
| Sep 28, 2025 | 2.34 Bn |
| Jun 29, 2025 | 954.00 Mn |
| Mar 30, 2025 | 2.63 Bn |
| Dec 29, 2024 | 456.00 Mn |
| Sep 29, 2024 | 644.00 Mn |
| Jun 30, 2024 | 1.06 Bn |
| Mar 31, 2024 | 459.00 Mn |
| Dec 31, 2023 | 694.00 Mn |
| Oct 1, 2023 | 908.00 Mn |
| Jul 2, 2023 | 930.00 Mn |
| Apr 2, 2023 | -796.00 Mn |
| Jan 1, 2023 | 1.19 Bn |
| Oct 2, 2022 | 862.00 Mn |
| Jul 3, 2022 | 1.03 Bn |
| Apr 3, 2022 | 713.00 Mn |
| Oct 3, 2021 | 182.00 Mn |
| Jul 4, 2021 | 384.00 Mn |
| Apr 4, 2021 | 1.23 Bn |